Previous 10 | Next 10 |
Patient Achieved Stable Disease BEVERLY HILLS, CA / ACCESSWIRE / March 31, 2020 / GT Biopharma, Inc. (OTCQB:GTBP);(GTBP.PA) a company focused on developing innovative therapeutic treatments based on its proprietary NK cell engager TriKE™ platform announced today that it has been ...
Patient Achieves Stable Disease BEVERLY HILLS, CA / ACCESSWIRE / March 19, 2020 / GT Biopharma, Inc. (OTCQB:GTBP) (GTBP.PA) a biotherapeutics company focused on developing innovative therapeutic treatments in oncology and infectious diseases based on its proprietary NK cell engager TriK...
BEVERLY HILLS, CA / ACCESSWIRE / March 19, 2020 / GT Biopharma, Inc. (OTCQB:GTBP)(GTBP.PA) a biotherapeutics company focused on developing innovative therapeutic treatments in oncology and infectious diseases based on its proprietary NK cell engager TriKE™ platform announced today tha...
Thinly traded nano cap GT Biopharma ( OTCQB:GTBP +20% ) is, yet another, would-be player in the rush to develop a drug to treat COVID-19. More news on: GT Biopharma, Inc., Healthcare stocks news, Stocks on the move, Read more ...
BEVERLY HILLS, CA / ACCESSWIRE / March 10, 2020 / GT Biopharma, Inc. (OTCQB:GTBP)(GTBP.PA) a company focused on developing innovative therapeutic treatments based on its proprietary NK cell engager (TriKE™) platform announced today that it had entered into a collaboration agreement wi...
GT Biopharma ( OTCQB:GTBP ) says the first patient has been dosed in a Phase I/II clinical trial of its anti-CD16/IL-15/anti-CD33 TriKE, GTB-3550. More news on: GT Biopharma, Inc., Healthcare stocks news, Read more ...
TAMPA, FL / ACCESSWIRE / February 26, 2020 / GT Biopharma, Inc. (OTCQB:GTBP)(GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKE™) platform announced today that the first patient has been dosed in a Phase I/II ...
BEVERLY HILLS, CA / ACCESSWIRE / January 21, 2020 / GT Biopharma, Inc. (OTCQB:GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary TriKE™ NK cell engager platform provided the following update concerning its drug development pr...
TAMPA, Florida , Oct. 22, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKE™) platform, announced today that Drs. Jeffrey Miller , Martin Felic...
TAMPA, Florida , Oct. 3, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA), an immuno-oncology company focused on innovative treatments based on the Company's patent pending TriKE™ technology, announced today that Tim Schacker , M.D., Jeffrey S. Miller , M.D., and t...
News, Short Squeeze, Breakout and More Instantly...
GTB-3650 Phase 1 trial initiation expected in H2 2024; initial clinical data expected in H1 2025 GTB-5550 TriKE ® IND submission for treatment of B7H3 positive solid tumors expected in Q1 2025 GTB-5550 Phase 1 dose escalation basket trial initiation expected in 20...
BRISBANE, CALIFORNIA, May 21, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), today announced that it has entered into a definitive securities purchase agreements for the purchase and sale of 740,000 shares of the Company’s common stock at a purcha...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 16.4% to $0.199 on volume of 720,586,242 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 74.8% to $1.8 on volume of 682,362,254 shares Pineapple Energy Inc. (PEGY) rose 80.3% to $0.1...